Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alignment Healthcare (ALHC) Gains from Investment Securities (2020 - 2025)

Historic Gains from Investment Securities for Alignment Healthcare (ALHC) over the last 5 years, with Q2 2025 value amounting to $72000.0.

  • Alignment Healthcare's Gains from Investment Securities changed N/A to $72000.0 in Q2 2025 from the same period last year, while for Sep 2025 it was $72000.0, marking a year-over-year decrease of 7942.86%. This contributed to the annual value of $350000.0 for FY2024, which is N/A changed from last year.
  • Latest data reveals that Alignment Healthcare reported Gains from Investment Securities of $72000.0 as of Q2 2025.
  • Over the past 5 years, Alignment Healthcare's Gains from Investment Securities peaked at $10.6 million during Q1 2023, and registered a low of -$101000.0 during Q4 2022.
  • Moreover, its 4-year median value for Gains from Investment Securities was $5.3 million (2023), whereas its average is $5.3 million.
  • Over the last 5 years, Alignment Healthcare's Gains from Investment Securities had its largest YoY gain of 9669.32% in 2024, and its largest YoY loss of 9669.32% in 2024.
  • Over the past 4 years, Alignment Healthcare's Gains from Investment Securities (Quarter) stood at -$101000.0 in 2022, then skyrocketed by 10270.33% to $10.3 million in 2023, then crashed by 96.59% to $350000.0 in 2024, then tumbled by 79.43% to $72000.0 in 2025.
  • Its Gains from Investment Securities stands at $72000.0 for Q2 2025, versus $350000.0 for Q1 2024 and $10.3 million for Q3 2023.